Antiproliferative effects of four different cytokines on renal carcinoma cell lines

H Buszello1

  • 1Department of Urology, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany.

Insights

Cytokines like gamma-interferon (gamma-IFN) and alpha-interferon (alpha-IFN) showed antiproliferative effects on renal cancer cell lines. Tumor necrosis factor alpha (TNF-alpha) and interleukin-2 (IL-2) demonstrated minimal to no impact on cancer cell growth.

Area of Science:

  • Immunology
  • Oncology
  • Cell Biology

Background:

  • Cytokines are crucial signaling molecules in immune responses.
  • Understanding cytokine effects on cancer cells is vital for targeted therapies.
  • Renal cell carcinoma (RCC) remains a significant health concern with limited treatment options.

Purpose of the Study:

  • To investigate the antiproliferative effects of four key cytokines on renal cancer cell lines.
  • To compare the efficacy of alpha-interferon (alpha-IFN), gamma-interferon (gamma-IFN), tumor necrosis factor alpha (TNF-alpha), and interleukin-2 (IL-2).

Main Methods:

  • Two human renal cancer cell lines (DNT-11 and HTB-44) were utilized.
  • Cells were incubated with varying concentrations of alpha-IFN, gamma-IFN, TNF-alpha, and IL-2 for 72 hours.
  • Cell proliferation was quantified using a tetrazolium-based microculture assay (MTT).

Main Results:

  • Gamma-interferon (gamma-IFN) reduced proliferation by 26-37%, while alpha-interferon (alpha-IFN) showed a 22-26% reduction.
  • Tumor necrosis factor alpha (TNF-alpha) exhibited minimal antiproliferative effects (up to 15%) on one cell line.
  • Interleukin-2 (IL-2) did not significantly affect the proliferation of either renal cancer cell line.
  • Prolonging incubation beyond 72 hours did not enhance the observed antiproliferative effects.

Conclusions:

  • Gamma-interferon and alpha-interferon show potential as therapeutic agents against renal cancer cell lines.
  • TNF-alpha and IL-2 appear to have limited direct antiproliferative activity on these specific renal cancer models.
  • Further research into cytokine combinations and mechanisms may yield more effective cancer treatments.